Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer
- PMID: 34139270
- DOI: 10.1016/j.annonc.2021.06.005
Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer
Conflict of interest statement
Disclosure RI served as consultant for Astellas, BMS, Ipsen, Janssen, Merk, MSD, Novartis, Pfizer, and Sanofi and received research grant from Pfizer. GT served as consultant for BMS and MSD. CC has declared no conflicts of interests.
Comment on
-
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.Ann Oncol. 2021 Jul;32(7):896-905. doi: 10.1016/j.annonc.2021.03.205. Epub 2021 Apr 6. Ann Oncol. 2021. PMID: 33836265 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
